Revelation Biosciences (REVB) AI Stock Analysis

• Market Cap: $2.76M
• Dividend Yield: N/A
• Average Volume (3M): 108.43K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.43
• Revenue Growth: N/A
• EPS Growth: -115.81%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 70
• Industry: Biotechnology
• EPS (TTM): -139.82
• Shares Outstanding: 905,228
• 10 Day Avg. Volume: 59,956
• 30 Day Avg. Volume: 108,434
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -1.43
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $20.00
• Price Target Upside: 555.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

Revelation Biosciences is heavily challenged financially with no revenue and persistent losses. Technical indicators suggest bearish momentum, while valuation metrics reflect severe investor concerns, particularly due to the negative P/E ratio. The company's reliance on external financing due to negative cash flows adds to the risk profile.

Revelation Biosciences Business Overview & Revenue Model

Company Description

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

How the Company Makes Money

Revelation Biosciences generates revenue primarily through the development and commercialization of its therapeutic candidates. The company's revenue model may include research and development collaborations, licensing agreements, and potential future product sales. Key revenue streams likely involve partnerships with larger pharmaceutical companies for joint development or commercialization efforts, as well as securing funding through grants or investments to support ongoing research. Currently, as a clinical-stage company, significant earnings may not be realized until products receive regulatory approval and reach the market.

Revelation Biosciences Financial Statement Overview

Summary

Revelation Biosciences faces significant financial challenges with no revenue generation and persistent losses. While the balance sheet is not burdened by debt, the dependence on external financing raises concerns about future liquidity. The ongoing negative cash flow highlights the urgent need for strategic changes to improve financial health.

Income Statement

Revelation Biosciences has no revenue over the reported periods, which is concerning for any growth trajectory. The company consistently reports negative EBIT and net income, indicating ongoing losses with no apparent path to profitability. The absence of revenue growth and negative margins are significant weaknesses.

Balance Sheet

The balance sheet shows a relatively strong equity position with no debt, which reduces financial risk. However, the company has negative net income, impacting the return on equity. The equity ratio is reasonable but challenged by the continual losses and lack of revenue generation.

Cash Flow

The cash flow statement reveals negative operating and free cash flow, which is a red flag for sustainability. The company heavily relies on financing activities to cover cash flow deficiencies, which is not sustainable long-term. The cash flow to net income ratios are unfavorable due to ongoing losses.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
0.00	-25.05K	-40.01K	-69.17K	0.00
	EBIT
-7.98B	-8.66M	-10.86M	-11.95M	-145.49K
	EBITDA
-7.98B	-95.21K	-10.84M	-11.93M	-145.49K
	Net Income Common Stockholders
-15.04B	-120.25K	-10.79M	-11.99M	-1.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.50B	11.99M	5.25M	1.27M	4.49M
	Total Assets
6.62B	12.21M	5.50M	2.04M	4.62M
	Total Debt
0.00	0.00	0.00	16.75K	0.00
	Net Debt
-6.50M	-11.99M	-5.25M	-1.26M	-4.49M
	Total Liabilities
1.91B	5.56M	4.45M	2.14M	1.21M
	Stockholders Equity
4.71B	6.65M	1.05M	-99.47K	3.41M
Cash Flow		Free Cash Flow
-18.34B	-7.29M	-11.22M	-11.22M	-215.07K
	Operating Cash Flow
-18.32B	-7.29M	-11.22M	-11.09M	-215.07K
	Investing Cash Flow
-19.17M	0.00	0.00	-131.96K	-74.04M
	Financing Cash Flow
12.85B	14.03M	15.20M	8.00M	74.26M

Revelation Biosciences Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.05
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Neutral. The current price of 3.05 is above the 20-day moving average (MA) of 3.03, below the 50-day MA of 3.21, and below the 200-day MA of 10.40, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 49.11 is Neutral, neither overbought nor oversold. The STOCH value of 25.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for REVB.

Revelation Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$5.38B	3.59	-41.63%	2.87%	17.72%	1.87%
APVO	38 Underperform	$2.94M	―	-284.28%	―	―	83.04%
ENSC	32 Underperform	$3.49M	―	-471.82%	―	133.58%	82.60%
REVB	28 Underperform	$2.76M	―	-264.85%	―	―	-115.81%
ENVB	24 Underperform	$3.26M	―	-356.82%	―	―	82.47%